---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000066"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-07-08T23:59:59+00:00"
generated_at: "2026-05-18T09:05:54.380593+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Salarius stockholders approve reverse stock split and Nasdaq 20% share issuance

## Summary
- Reverse stock split approved at ratio of 1:4 to 1:40; Board retains discretion on timing and exact ratio.
- Nasdaq 20% issuance proposal passed, authorizing shares under December 2024 purchase agreement with C/M Capital Master Fund, LP.
- Adjournment proposal passed but was not needed; quorum of 37.10% (789,213 of 2,127,286 shares) was present.
- Reverse split vote: 561,364 for, 224,901 against; issuance vote: 124,631 for, 73,764 against (589,723 broker non-votes).

## SEC filing metadata
- accession: 0001615219-25-000066
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-07-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000066/0001615219-25-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000066/flks-20250708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000066
- JSON: https://secwatch.observer/filing/0001615219-25-000066.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.